Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Clinical trial NCT02988843 · TERMINATED
Trial details
- NCT number
- NCT02988843
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-29
- Primary completion
- 2019-12-15
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.